Compound Access
Country Access Report
Medical Access and Reimbursement in Israel
Israel has documented public/HMO access to intranasal esketamine under criteria, while racemic ketamine is off-label and payer-specific. Classical psychedelics remain controlled, investigational or exceptional-access therapies rather than routine reimbursed medicines.
- Access Level
- Public Esketamine + Trials Only
- Compounds Covered
- 10
- Active Trials
- 5
Access by Compound
Compound-specific notes summarise what is realistically available through approved medical use, clinical research, exceptional access, or private care where the country report has verifiable information.
Compound Access
MDMA
Compound Access
Esketamine
Compound Access
Ketamine
Compound Access
DMT
Compound Access
5-MeO-DMT
Compound Access
Ibogaine
Compound Access
Ayahuasca
Compound Access
Mescaline
Mescaline should be treated as a controlled classical psychedelic in Israel. No routine medical access or reimbursement pathway was identified. #
Compound Access
2C-X
Sources and Verification
Last updated 13 May 2026. Source links are drawn from citation annotations in the medical access and reimbursement guide.
- 1Hebrew University psilocybin paper
- 2Israel controlled substances import service
- 3Israel Dangerous Drugs Ordinance
- 4Israel Ministry of Health depression care page
- 5Israel Regulation 29 district pharmacy approval
- 6Israel Spravato patient safety card
- 7Israeli real-world esketamine paper
- 8Maccabi Spravato eligibility page
- 9MAPS Israel MDMA compassionate use notice
- 10Shalvata ketamine route comparison record
- 11Sheba MDMA PTSD trial record